J.C.-H. Yang

499 total citations · 1 hit paper
12 papers, 353 citations indexed

About

J.C.-H. Yang is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, J.C.-H. Yang has authored 12 papers receiving a total of 353 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 4 papers in Molecular Biology. Recurrent topics in J.C.-H. Yang's work include Lung Cancer Treatments and Mutations (10 papers), Lung Cancer Research Studies (9 papers) and Cancer therapeutics and mechanisms (3 papers). J.C.-H. Yang is often cited by papers focused on Lung Cancer Treatments and Mutations (10 papers), Lung Cancer Research Studies (9 papers) and Cancer therapeutics and mechanisms (3 papers). J.C.-H. Yang collaborates with scholars based in Taiwan, United States and Canada. J.C.-H. Yang's co-authors include Helen Mann, Suresh S. Ramalingam, Seung‐Whan Kim, Geoffrey R. Oxnard, Myung‐Ju Ahn, Leora Horn, Kenneth S. Thress, Dana Ghiorghiu, Helena A. Yu and Yuichiro Ohe and has published in prestigious journals such as Annals of Oncology, Journal of Thoracic Oncology and The Chinese-German Journal of Clinical Oncology.

In The Last Decade

J.C.-H. Yang

12 papers receiving 351 citations

Hit Papers

TATTON: a multi-arm, phase Ib trial of osimertinib combin... 2020 2026 2022 2024 2020 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
    2020 303 citations Geoffrey R. Oxnard, J.C.-H. Yang et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J.C.-H. Yang Taiwan 5 281 263 94 46 34 12 353
L. Paz-Ares Spain 9 215 0.8× 291 1.1× 97 1.0× 40 0.9× 25 0.7× 51 374
Giulia Grizzi Italy 12 185 0.7× 262 1.0× 82 0.9× 70 1.5× 30 0.9× 24 370
M.R. García Campelo Spain 9 301 1.1× 284 1.1× 119 1.3× 90 2.0× 15 0.4× 35 387
B.C. Cho South Korea 8 232 0.8× 204 0.8× 90 1.0× 47 1.0× 15 0.4× 33 280
Aurélie Swalduz France 11 200 0.7× 182 0.7× 126 1.3× 92 2.0× 28 0.8× 63 334
Zhenkui Pan China 10 302 1.1× 312 1.2× 74 0.8× 80 1.7× 50 1.5× 12 423
Yoshiko Urata Japan 11 237 0.8× 241 0.9× 51 0.5× 33 0.7× 16 0.5× 34 322
Stephanie P.L. Saw Singapore 6 166 0.6× 138 0.5× 68 0.7× 54 1.2× 25 0.7× 14 278
Umair Majeed United States 5 159 0.6× 149 0.6× 95 1.0× 81 1.8× 19 0.6× 27 295
J.-S. Lee South Korea 7 200 0.7× 268 1.0× 66 0.7× 37 0.8× 22 0.6× 17 310

Countries citing papers authored by J.C.-H. Yang

Since Specialization
Citations

This map shows the geographic impact of J.C.-H. Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J.C.-H. Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J.C.-H. Yang more than expected).

Fields of papers citing papers by J.C.-H. Yang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J.C.-H. Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J.C.-H. Yang. The network helps show where J.C.-H. Yang may publish in the future.

Co-authorship network of co-authors of J.C.-H. Yang

This figure shows the co-authorship network connecting the top 25 collaborators of J.C.-H. Yang. A scholar is included among the top collaborators of J.C.-H. Yang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J.C.-H. Yang. J.C.-H. Yang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
2.
3.
Kim, Hye Ryun, Mark M. Awad, Alejandro Navarro, et al.. (2020). 1782MO Health-related quality of life (HRQoL) in KEYNOTE-604: Pembrolizumab (pembro) or placebo added to etoposide and platinum (EP) as first-line therapy for ES-SCLC. Annals of Oncology. 31. S1033–S1034. 4 indexed citations
4.
Oxnard, Geoffrey R., J.C.-H. Yang, Helena A. Yu, et al.. (2020). TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer. Annals of Oncology. 31(4). 507–516. 303 indexed citations breakdown →
5.
6.
7.
Gutierrez, Martin, Wei‐Sen Lam, Matthew D. Hellmann, et al.. (2019). KEYNOTE-495/KeyImPaCT: A randomized, biomarker-directed, phase II trial of pembrolizumab-based therapy for non–small cell lung cancer (NSCLC). Annals of Oncology. 30. v656–v656. 2 indexed citations
8.
Sequist, Lecia V., Yi‐Long Wu, Martin Schüler, et al.. (2017). Subsequent therapies post-afatinib among patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC in LUX-Lung (LL) 3, 6 and 7. Annals of Oncology. 28. v482–v483. 10 indexed citations
9.
10.
Langer, Corey J., Hossein Borghaei, Vassiliki A. Papadimitrakopoulou, et al.. (2016). Randomized, phase 2 study of carboplatin and pemetrexed with or without pembrolizumab as first-line therapy for advanced NSCLC: KEYNOTE-021 cohort G. Annals of Oncology. 27. vi582–vi582. 8 indexed citations
11.
12.
Ding, Guanghui, Hongyang Wang, Han Chen, et al.. (2005). Expression of the Glypican-3 Gene in α-fetoprotein-negative Human Hepatocellular Carcinoma. The Chinese-German Journal of Clinical Oncology. 4(5). 262–266. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by L. Paz-Ares Breakdown of academic impact, for papers by Giulia Grizzi Breakdown of academic impact, for papers by M.R. García Campelo Breakdown of academic impact, for papers by B.C. Cho Breakdown of academic impact, for papers by Aurélie Swalduz Breakdown of academic impact, for papers by Zhenkui Pan Breakdown of academic impact, for papers by Yoshiko Urata Breakdown of academic impact, for papers by Stephanie P.L. Saw Breakdown of academic impact, for papers by Umair Majeed Breakdown of academic impact, for papers by J.-S. Lee
Rankless by CCL
2026